Hyperglycemia Treatment Market Trends, Demand, Regional Analysis and Forecast 20Posted by Apeksha on July 19th, 2021 Hyperglycemia Treatment Market Information: By Treatment (Fluid Replacement, Electrolyte Replacement, Insulin Therapy, Drugs), Mode of Administration (Topical, Oral), End User (Hospitals & Clinics, Retail Pharmacy) - Global Forecast till 2027 Market Highlights Hyperglycemia is a disorder caused by increased blood glucose (blood sugar) level. Hyperglycemia is a sign of diabetes including both type 1 diabetes and type 2 diabetes. Insulin therapy is one of the treatment for patient with type 1 diabetes. Increasing prevalence of diabetes, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. The global hyperglycemia treatment market is expected to grow at a CAGR of 9.8 % during the forecast period 2017-2023. Regional Analysis The Americas dominates the global hyperglycemia treatment market owing to the presence of huge patient population with diabetes, neurological disorder, high healthcare spending, and increasing government support for research & development. Europe holds the second largest share of the global hyperglycemia treatment market as result of increasing focus of various government agencies on the treatment of hyperglycemia and cardiovascular diseases. Moreover, the growing public awareness about hyperglycemia likely to boost the adoption of these devices in the Europe market. Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/hyperglycemia-treatment-market-4565 Key Players Some of key the players in the market are Novo Nordisk A/S, Merck & Company Inc., Medtronic, Johnson & Johnson Services, Inc. , Teva Pharmaceuticals Ltd., Eli Lilly and Company, Sanofi S.A., Home Diagnostics, Bayer AG, Bristol-Myers Squibb., and Abbott. Contact: Akash Anand Market Research Future +1 646 845 9312 Like it? Share it! More by this author |